( A ) Intracellular accumulation of cAMP was measured by enzymatic immunoassay in lysates from caSMCs treated for 10 minutes with 100 nM each of GLP-1, forskolin, or PBS control, with or without 20 M sacubitril, a neutral endopeptidase inhibitor ( n = 3/treatment, each in triplicate)
In December 2023, Medifast partnered with LifeMD, an online primary care platform, to integrate GLP-1 management and prescribing features into its Optavia weight loss program
Both models are based on Cox proportional hazards regression, trained to predict time-to-death from DNAm profiles
It's now FSA-approved
Appetite Cravings Impacts areas of the brain that regulate appetite, leading to reduced hunger and increased feelings of fullness
In the 72-week STEP UP trial, in adults with obesity along with diet and exercise, Wegovy HD (semaglutide) injection 7.2 mg significantly reduced body weight 1 * Analysis of all patients regardless of if they stayed on treatment 7 Co-primary end point: Percent change in body weight 1* Co-primary end point: Reduction in body weight of 5% 1 * Proportion of patients achieving 5% weight loss at 72 weeks * Confirmatory secondary end points (week 72) 1 * 10% weight loss: 79.8% Wegovy HD vs 20.3% placebo 15% weight loss: 63.8% Wegovy HD vs 7.5% placebo 20% weight loss: 45.5% Wegovy HD vs 2.8% placebo ~1 in 3 people (31.2%) of patients achieved 7 * vs 0% of patients with placebo If all patients stayed on treatment 7 20.7% mean weight loss with Wegovy HD vs 2.4% (6 lb) placebo at 72 weeks, in an idealized scenario estimating efficacy if patients remained on treatment for the duration of the trial and used no other weight-loss therapies 7 Mean baseline body weight: Wegovy HD=247.8 lb
